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Abstract: Sepsis is the manifestation of the immune and inflammatory response to 
infection that may ultimately result in multi organ failure. Despite the therapeutic strategies 
that have been used up to now, sepsis and septic shock remain a leading cause of death in 
critically ill patients. Myocardial dysfunction is a well-described complication of severe 
sepsis, also referred to as septic cardiomyopathy, which may progress to right and left 
ventricular pump failure. Many substances and mechanisms seem to be involved in 
myocardial dysfunction in sepsis, including toxins, cytokines, nitric oxide, complement 
activation, apoptosis and energy metabolic derangements. Nevertheless, the precise 
underlying molecular mechanisms as well as their significance in the pathogenesis of 
septic cardiomyopathy remain incompletely understood. A well-investigated abnormality 
in septic cardiomyopathy is mitochondrial dysfunction, which likely contributes to cardiac 
dysfunction by causing myocardial energy depletion. A number of mechanisms have been 
proposed to cause mitochondrial dysfunction in septic cardiomyopathy, although it remains 
controversially discussed whether some mechanisms impair mitochondrial function or serve 
to restore mitochondrial function. The purpose of this review is to discuss mitochondrial 
mechanisms that may causally contribute to mitochondrial dysfunction and/or may represent 
adaptive responses to mitochondrial dysfunction in septic cardiomyopathy. 
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1. Introduction 
Sepsis is responsible for millions of deaths worldwide each year and is a frequent cause of death in 
people who have been hospitalized [1]. In the United States, 3 in 1000 people suffer from sepsis,  
and severe sepsis contributes to more than 200,000 deaths per year [2]. Sepsis is the manifestation of 
the immune and inflammatory response to infection that may ultimately result in multi organ failure.  
It is believed that the release of pro-inflammatory mediators is not answered by an appropriate  
anti-inflammatory response and overwhelms the immune system, resulting in an uncontrolled 
excessive inflammatory state and an inability to neutralize pathogens [3]. Both effects of bacterial 
endotoxins and exotoxins, as well as an excessive release of a large number of cytokines contribute to 
organ dysfunction and failure during sepsis and septic shock. Guidelines recommend early treatment 
with antibiotics, to restore fluid deficits, and vasopressor treatment if necessary, actions that are critical 
for patient outcomes and overall survival. Besides specifically neutralizing the pathogen with antibiotics, 
the currently recommended therapeutic strategies are symptomatic, and no specific treatment is available 
to treat the consequences of specific organ damage in sepsis. 
End-organ damage and organ failure in sepsis affects the most significant organs of the body, 
including the heart. Myocardial dysfunction is a well-described complication of severe sepsis, also 
referred to as septic cardiomyopathy, which includes both systolic and diastolic dysfunction [4]. 
Adequate O2 supply in sepsis suggests that myocardial depression is not related to tissue hypoperfusion 
but to the presence of circulating depressant factors, or other mechanisms [5]. A number of mechanisms 
have been proposed to be involved in myocardial dysfunction in sepsis, including toxins, cytokines, 
nitric oxide, complement activation, apoptosis and energy metabolic derangements [6,7]. The latter 
two mechanisms imply that mitochondrial function may be compromised in septic cardiomyopathy. 
Already a century ago, it had been recognized that low arterial oxygen tension, low circulating 
hemoglobin levels and/or tissue hypoperfusion may lead to tissue hypoxia during sepsis, thereby 
contributing to impaired ATP generation [8–10]. Others demonstrated that these parameters were not 
impaired or even improved during sepsis [11,12]. Instead, more recent studies strongly suggest that 
organ dysfunction in sepsis, including myocardial depression, is rather related to the presence of 
circulating depressant factors or other mechanisms, leading to cellular energy depletion [5]. 
Indeed, a number of studies identified myocardial mitochondrial dysfunction in septic conditions 
both in animal models and humans [13–18]. Since the heart is highly dependent on continuous delivery 
of ATP to maintain contractile function, impairment in mitochondrial function is energetically detrimental 
for the heart. For a number of cardiac pathologies, mitochondrial dysfunction and energy depletion 
have been proposed to significantly contribute to cardiac dysfunction, including prevalent cardiac 
diseases such as ischemia reperfusion injury, diabetic cardiomyopathy and heart failure [19–21]. While 
a number of mechanisms have been proposed to causally contribute to myocardial mitochondrial 
dysfunction in sepsis, a number of other mitochondria-related alterations occur in septic cardiomyopathy 
the purpose of which may be to restore mitochondrial function. In the following sections, we will 
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review the evidence of mitochondrial dysfunction in septic cardiomyopathy and discuss mitochondrial 
mechanisms that may causally contribute to mitochondrial dysfunction and/or may represent adaptive 
responses to mitochondrial dysfunction in septic cardiomyopathy. 
2. Myocardial Mitochondrial Dysfunction in Sepsis 
In the heart, high-energy phosphates are mainly generated from the oxidation of fatty acids, while 
glucose and other substrates contribute to myocardial ATP regeneration to a lesser extent. Substrate 
oxidation yields mainly NADH (reduced nicotinamide adenine dinucleotide) and FADH2 (reduced 
flavin adenine dinucleotide), which feed electrons into the electron transport chain of oxidative 
phosphorylation (OXPHOS) via complex I and II. Electron transport results in the reduction of O2 to 
H2O, which is coupled to ATP regeneration by the F0F1-ATPase (ATP synthase). ATP exits the 
mitochondrion and is mainly utilized by myosin ATPases to maintain contractile function, whereas  
a minor part of ATP is used to maintain cellular ion homeostasis. Of note, the entire pool of 
myocardial ATP is turned over completely every few seconds, emphasizing that mitochondrial energy 
substrate metabolism is critically important to maintain ATP availability and thus cardiac function. 
Mitochondrial dysfunction is widely discussed as a crucial mechanism of organ dysfunction in sepsis, 
including the heart, although only few data on mitochondrial function are available from human  
septic hearts. Takasu and colleagues reported edema of the mitochondrial matrix, associated with 
cystic alterations of the cristae and collapse into small myelin-like clusters in hearts of septic  
patients [22]. Soriano et al. observed that patients that did not survive sepsis presented a more severe 
degree of cardiac dysfunction compared to survivors, and non-survivors also showed derangements in 
mitochondrial cristae [13]. In contrast, numerous animal studies reported myocardial mitochondrial 
dysfunction in sepsis. The most commonly used animal models of sepsis are the induction of sepsis by 
injection of an exogenous bacterial toxin, mostly lipopolysaccharide (LPS), or the induction of intestinal 
leakage by cecal ligation and puncture (CLP) or colon ascendant stent peritonitis (CASP) [23].  
Using these models, it was well documented by Smeding and colleagues [24] that, in the majority  
of the cases, the impairment in cardiac mitochondrial function correlated with decreased cardiac 
contractility, both measured in vivo by echochardiography or ex vivo in the isolated heart perfusion. 
Mitochondrial dysfunction was characterized by decreased rates of State 3 respiration and ATP 
synthesis, decreased respiratory control ratios and membrane potential, decreased activities of 
mitochondrial OXPHOS Complexes, increased rates of State 4 respiration, and increased mitochondrial 
size and fragility [14,25–29]. Several authors reported a decrease in State 3 respiration in the heart 
using glutamate as a Complex I substrate, whereas an impairment in Complex II-mediated respiration 
was less consistent [29–31]. Decreased activity or expression of individual OXPHOS Complexes was 
also widely reported, in particular Complex I. Decreased State 3 respiration was frequently associated 
with a decreased respiratory control ratio (RCR), although the lower RCR was sometimes related to 
increased State 4 respiration [26], which could be indicative of mitochondrial uncoupling. In addition,  
a decrease of the mitochondrial transmembrane potential (Δψ) or increased mitochondrial permeability 
transition was often observed in animal models of sepsis. Functional impairment of cardiac mitochondria 
was often associated with structural defects of mitochondria, such as cristae derangement, cleared matrix 
and mitochondrial swelling in animal models, thereby confirming the findings in human septic hearts 
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as described above. Finally, increased mitochondrial reactive oxygen species (ROS) generation also 
confirms dysfunction of mitochondria in septic cardiomyopathy [32]. 
Although mitochondrial dysfunction in septic cardiomyopathy is associated with cardiac dysfunction, 
the underlying mechanisms of mitochondrial dysfunction are still incompletely elucidated. In addition, 
a number of mitochondrial mechanisms are triggered in septic cardiomyopathy, which may rather 
serve to restore than impair mitochondrial function, although controversially discussed. In the 
following sections, we will discuss mitochondrial mechanisms that may causally contribute to 
mitochondrial dysfunction and/or may represent adaptive responses to mitochondrial dysfunction in 
septic cardiomyopathy (illustrated in Figure 1). 
 
Figure 1. Mitochondrial mechanisms in septic cardiomyopathy: Increased superoxide (O2·−) 
and nitric oxide (NO) production can cause direct oxidative or nitrosative damage and 
inhibition of oxidative phosphorylation (OXPHOS) complexes, leading to decreased O2 
consumption and decreased mitochondrial membrane potential (Δψ). In addition, Δψ may 
drop due to increased uncoupling protein (UCP)-mediated proton leak, increased Ca2+-induced 
mitochondrial permeability transition pore (mPTP) opening and direct oxidative damage of 
the inner mitochondrial membrane. As a consequence, mitochondrial ATP regeneration  
is compromised, and energy depletion may contribute to cardiac contractile dysfunction. 
Increased mitophagy may eliminate dysfunctional mitochondria, which may be replaced by 
increased mitochondrial biogenesis, mediated by activation of peroxisome proliferator-activated 
receptor γ coactivator 1α/β (PGC-1α/β). However, if uncoordinatedly activated, mitophagy 
and mitochondrial biogenesis may lead to decreased mitochondrial mass and dysfunctional 
mitochondria (upward pointing arrow: increase; downward pointing arrow: decrease; 
dashed arrow: possible consequence). 
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3. Mechanisms of Myocardial Mitochondrial Dysfunction in Sepsis 
3.1. Mitochondrial NO Production and Oxidative Stress 
During respiration, mitochondria may reduce O2 univalently thereby producing O2·− (superoxide anion) 
as a normal metabolite. Under physiological conditions, only a small percentage (1%–2%) of the O2 
utilized is driven to O2·− formation, which is dismutated to H2O2 by Mn-superoxide dismutase. 
However, situations in which steady-state concentrations of these reactive oxygen species (ROS) are 
increased can lead to a diverse array of reversible and irreversible toxic modifications on biomolecules, 
such as protein carbonylation or lipid peroxidation. The continuous mitochondrial production of free 
radicals and the significant amount of mitochondria within cells makes mitochondria the most 
important source of these harmful species within the cell. At the same time, mitochondrial enzymes, 
function and mtDNA are particularly sensitive to ROS-induced damage [33,34]. Mitochondria also 
produce nitric oxide (NO) through the activity of mitochondrial NO synthase (mtNOS), which 
physiologically regulates mitochondrial respiration by inhibition of cytochrome c oxidase [35]. 
Sepsis is an excessive, systemic inflammatory response characterized by massive increases in ROS, 
NO and inflammatory cytokines [36]. A large body of evidence strongly suggests that excessive 
mitochondrial production of NO and ROS contribute to mitochondrial dysfunction in sepsis in  
various tissues, including the heart. Studies demonstrated that NO production, production of O2·− and 
H2O2, global protein nitration, nitrotyrosine content, protein carbonylation and lipid peroxidation  
are increased in cardiac mitochondria of animals subjected to endotoxemia [14,26,37–39]. Moreover, 
the antioxidant systems, aimed to scavenge these reactive species, seem to be inhibited as shown  
by decreased activity of Mn-superoxide dismutase and glutathione peroxidase, and depletion of 
gutathione [40,41]. Peroxynitrite (ONOO−) is a particularly powerful oxidant, which results from  
a diffusion-controlled reaction of NO with O2·−. In a model of CLP, Escames et al. showed increased 
activity of the inducible mitochondrial nitric oxide synthase (i-mtNOS) in septic mice, which leads to 
increased mitochondrial ONOO− levels [42,43]. Increased oxidative stress, impairment in OXPHOS 
function and a decrease in ATP production were restored by genetic deletion of iNOS (iNOS−/− mice), 
which also includes the mitochondrial isoform, suggesting a significant role of ONOO− in myocardial 
mitochondrial dysfunction in sepsis [43]. This argument is further supported by the fact that treatment 
with melatonin, an inhibitor of iNOS, prevented the impairment of mitochondrial homeostasis after 
sepsis, restored ATP production and improved survival. Some studies also showed an improvement  
of cardiac function by pharmacological inhibition or genetic deletion of NOS in septic animal  
models [37,44]. One of these studies showed that recovery of NO production and content of NO 
metabolites in mitochondria was associated with partial improvement of left ventricular (LV) 
developed pressure. A causal relationship between mitochondrial NO production and cardiac 
dysfunction needs to be considered carefully though, since NO is produced by several NOS isoforms 
(not only mitochondrial) at different intracellular locations and in different cell types, and since the 
role of NO in cardiovascular function and regulation of vascular tone is indisputably contributing to 
cardiac dysfunction in sepsis. 
While increased ROS levels in sepsis may origin from ROS production at different cellular sites,  
the importance of mitochondrial oxidative stress in animal models of sepsis has been underlined by 
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studies demonstrating beneficial effects by treatment with mitochondria-targeted antioxidants. 
Treatment with α-lipoic acid, an antioxidant that is reduced in the mitochondria to a more active form 
(dihyrolipoic acid), led to full recovery of cardiac mitochondrial function during endotoxemia [45]. 
Furthermore, administration of Coenzyme Q10 that was conjugated to triphenylphosphonium (MitoQ), 
a powerful mitochondria-targeted antioxidant, not only restored mitochondrial function but also 
ameliorated myocardial dysfunction in mice and rats treated with LPS [46]. Finally, treatment with 
vitamin E conjugated to triphenylphosphonium (Mito-VitE) in a rat pneumonia-related sepsis model 
prevented mitochondrial ROS production and ROS-related damage in the heart, with recovery of 
mitochondrial structure and function [32]. 
3.2. Ca2+ Handling and Mitochondrial Permeability Transition 
On the basis of the chemiosmotic model of energy transduction, the impermeability of the inner 
mitochondrial membrane is essential to allow the electron transport chain to pump protons across the 
inner mitochondrial membrane (IMM) and to build up a proton gradient that can be used by the  
F0F1-ATPase to regenerate ATP. Mitochondrial permeability transition is a sudden increase of IMM 
permeability for solutes with a molecular mass up to 1500 Da, and it is believed that this permeability 
transition is mediated by a voltage- and Ca2+-dependent, cyclosporin A (CsA)-sensitive, high-conductance 
channel located in the inner mitochondrial membrane termed mitochondrial permeability transition 
pore (mPTP). The consequence of mPTP opening is loss of Δψ, a decrease in State 3 respiration, 
mitochondrial swelling and rupture of the outer mitochondrial membrane, ultimately leading to 
activation of pro-apoptotic pathways and necrotic cell death. Ca2+ overload is the primary trigger of 
mPTP opening, but the sensitivity of the pore is dependent on prevailing conditions, such as oxidative 
stress, adenine nucleotide depletion, increased inorganic phosphate concentrations and mitochondrial 
depolarization [47]. Using the LPS-induced endotoxemia model in rats, Hassoun et al. observed 
decreased Ca2+ uptake into the sarcoplasmic reticulum and increased Ca2+ leak from this organelle, 
which was associated with increased mitochondrial Ca2+ content. Administration of the sarcoplasmic 
reticulum Ca2+ leak inhibitor dantrolene prevented mitochondrial Ca2+ overload, and improved 
mitochondrial dysfunction and cardiac contractility defects, suggesting that mitochondrial Ca2+ 
overload could be an important mechanism contributing to myocardial mitochondrial dysfunction in 
sepsis [30]. Larche and colleagues reported decreased survival, myocardial dysfunction, decreased 
State 3 and increased State 4 respiration, and increased opening of the mPTP in CLP-induced sepsis. 
Inhibition of the mPTP by CsA treatment improved cardiac function, survival, and also attenuated 
mitochondrial dysfunction in this study. In addition, the amount of Ca2+ required to increase mPTP 
opening in CLP-treated mice was less than 25% of the Ca2+ needed in control animals, indicative of 
increased sensitivity for Ca2+-induced mPTP opening of the mitochondria in CLP-treated mice [48]. In 
a different study by Fauvel et al., endotoxemic mice showed decreased LV developed pressure in 
isolated perfused hearts, and this contractile defect was rescued by in vivo treatment with CsA. 
Treatment with CsA also decreased caspase activation and cytochrome c release, suggestive of 
prevention of mPTP opening [49]. Chopra et al. observed severe morphological deformations that 
could be indicative of pore formation in rats treated with cecal inoculum, accompanied by  
a mitochondrial Δψ collapse. Restorative effects were observed in both parameters by treatment with  
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5-hydroxydecanoate (5-HD), a blocker of mitoKATP (mitochondrial ATP-sensitive K+ channel). 
Moreover, sepsis-related decreases in cardiac output and ejection fraction were recovered after 
inhibition of the mitoKATP [28]. The primary function of mitoKATP channels is thought to be the 
regulation of mitochondrial volume; mitoKATP channel opening results in mitochondrial uptake of 
potassium and associated inorganic phosphates, anions, and water [50], and is believed to sensitize 
outer membrane permeabilization and rupture in this sepsis model. Thus, it is tempting to speculate 
that in some models of sepsis, an impairment in cytosolic calcium handling may lead to mitochondrial 
Ca2+ overload, which triggers opening of a hypersensitive mPTP, thereby contributing to mitochondrial 
and contractile dysfunction. Further evidence is required to test whether activation of mitoKATP 
contributes to increased sensitivity for mPTP opening. It remains to be mentioned though that some 
studies reported no change of mPTP opening using the mitochondrial swelling assay, although Ca2+ 
handling was found to be impaired in isolated cardiomyocytes [51]. 
3.3. Mitochondrial Uncoupling 
Mitchell’s chemiosmotic theory of energy transduction states that the free energy generated by 
electron transport through the OXPHOS chain and ultimately transfer on O2 is used to set up  
an electrochemical H+ gradient across the inner mitochondrial membrane. Protons return into the 
matrix via the F0 subunit of the F0F1-ATPase, thereby regenerating ATP from ADP. Under 
physiological conditions, some H+ return into the matrix but bypass the F0F1-ATPase (e.g., via uncoupling 
proteins (UCPs)), resulting in “mitochondrial uncoupling” of ATP synthesis from O2 consumption. 
Physiologic uncoupling is used for heat generation in brown adipose tissue or to decrease 
mitochondrial ROS production [52]. Pathologic conditions with increased uncoupling include diabetic 
cardiomyopathy, where increased utilization of long-chain fatty acids results in ROS-induced activation 
of UCPs, resulting in decreased amounts of ATP per oxygen consumed and therefore impaired cardiac 
efficiency (cardiac work/myocardial O2 consumption) [53–55]. Similarly, an increase in UCP3 expression 
may increase mitochondrial uncoupling and decrease cardiac efficiency in chronically infarcted failing 
rat hearts [56]. 
The role of UCPs in sepsis remains controversial. Twelve hours following CLP, Roshon and 
colleagues found a 35% reduction in cardiac efficiency in isolated perfused hearts, probably due to  
a decrease in cardiac work and associated with increased UCP2 mRNA levels [57]. Similarly, 
myocardial mRNA content of both UCP2 and UCP3 were increased in LPS-induced endotoxemia  
in rats, and increased myocardial mRNA and protein expression of UCP2 was observed in a canine 
model of endotoxin-induced shock associated with decreased phosphocreatine/ATP ratios [41,58]. 
Thus, UCP-mediated uncoupling may impair cardiac efficiency under septic conditions. In contrast,  
a very recent study reported that treatment of rat embryonic cardiomyoblasts (H9C2) with LPS plus 
peptidoglycan G led to increased mRNA expression of UCP2, associated with decreased membrane 
potential, decreased ATP content, increased ROS and depletion of mtDNA. These effects were 
aggravated by additional silencing of UCP2, suggesting that increased UCP2 expression may actually 
exert protective effects [59]. Less and also controversial evidence is available on UCP3. Aguirre et al. 
showed increased myocardial UCP3 levels in LPS-induced endotoxemia [60]. These authors report 
decreased State 3 respiration and Complex IV activity in wildtype and UCP3−/− mice treated with LPS. 
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Proton conductance was found unchanged after 24 h of LPS treatment, regardless of the higher levels 
of UCP3. In contrast, UCP3 levels were increased with a concomitant loss of membrane potential and 
ATP content in neonatal cardiomyocytes treated with LPS [61]. 
3.4. Mitochondrial Biogenesis 
Mitochondrial biogenesis can be described as growth and division of mitochondria that requires the 
proper functioning of a number of cellular processes including the coordinated synthesis and import of 
proteins encoded by the nuclear genome, mtDNA replication, synthesis of proteins encoded by the 
mitochondrial genome and fusion–fission processes [62]. Mitochondrial biogenesis is triggered by 
different cellular stressors, such as increased levels of NO, oxidative stress, and an elevated AMP/ATP 
ratio, among others, resulting in the activation of the peroxisome proliferator-activated receptor y 
(PPARγ) coactivator (PGC) family of transcriptional coactivators, most importantly PGC-1α and  
PGC-1β [63,64]. PGC-1α coactivates and/or increases the expression of transcription factors,  
including ERRα/γ, NRF1/2 and Tfam, that mediate the transcription of nuclear and mitochondrially 
encoded OXPHOS subunits, nuclear proteins necessary for mtDNA transcription and replication, 
OXPHOS assembly factors, and components of mitochondrial protein import [65]. By regulating 
ERRα and PPARα, PGC-1α/β also stimulate the expression of genes encoding for proteins and 
enzymes of fatty acid oxidation, the main metabolic pathway of fuel oxidation in cardiac tissue. 
Several studies have illustrated that mitochondrial biogenesis or the process of generating new 
mitochondria improves survival in sepsis, and inhibition of mitochondrial biogenesis worsens  
outcome [25,66]. It is generally thought that loss and/or removal of damaged mitochondria in septic 
organs is compensated by generation of new mitochondria by increased mitochondrial biogenesis, 
which should be responsible for increasing survival and reversing organ damage. In the heart,  
Vanasco et al. recently reported increased myocardial levels of PGC1-α and Tfam, accompanied by 
increased mitochondrial mass and recovery of initially decreased amounts of mtDNA 24 h following 
LPS treatment [14]. Electron microscopy revealed an increased amount of structurally damaged 
mitochondria, including swelling, loss and/or disruption of cristae, cleared matrix, and internal vesicles. 
Despite evidence of mitochondrial biogenesis, mitochondrial State 3 respiration related to Complex I 
substrates and activity of Complexes I and II were impaired. Others also reported increased expression 
of mediators of mitochondrial biogenesis, including PGC-1α, NRF-1, and NRF-2, as well as Tfam and 
the mitochondrial DNA polymerase, associated with mitochondrial structural changes such as swelling 
and loss of cristae [41]. In neonatal cardiomyocytes, LPS treatment stimulated an increase in Tfam, 
nuclear accumulation of NRF-1, and expression of PGC-1α, and the changes correlated with signs of 
mitochondrial dysfunction (decreased mitochondrial membrane potential and ATP content) and 
markers of autophagy [61]. Taken together, it appears that mitochondrial biogenesis signaling is 
activated in endotoxemia, which however may not necessarily result in improvement or recovery of 
mitochondrial function. Russell and colleagues demonstrated that cardiomyocyte-specific overexpression 
of PGC-1α resulted in a markedly increased mitochondrial biogenesis but also heart failure [67]. 
Possibly, intensive stimulation of mitochondrial biogenesis might have perturbed the complex process 
of gene transcription and mitochondrial dynamics in this study, resulting in mitochondria with  
altered biochemical composition and stoichiometry and thus functional deficits. Thus, while being  
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a compensatory mechanism to overcome loss of dysfunctional mitochondria, uncontrolled triggering of 
mitochondrial biogenesis in endotoxemia may also result in dysfunctional mitochondria per se. 
Alternatively, mitochondrial biogenesis may simply not be sufficient to compensate for mitochondrial 
defects in septic conditions. 
In contrast to increased mitochondrial biogenesis signaling, Schilling et al. showed that LPS 
injection led to a rapid downregulation of PGC-1α and PGC-1β mRNA levels, accompanied by 
decreased levels of PPARα, ERRα, and NRF1. Cardiac function was depressed 6 h after the onset of 
endotoxemia, associated with a decrease in palmitate oxidation in the isolated working heart and 
increased myocyte lipid accumulation [68]. The total mtDNA copy number and mRNA levels of 
several enzymes were decreased, and the content of respiratory Complexes I and IV, assessed by  
2D-gel electrophoresis and MALDI-TOF mass spectrometry, was reduced in treated rats [41].  
Thus, time points and models investigated may affect initiation of mitochondrial biogenesis, and it 
remains controversial whether activation of mitochondrial biogenesis is actually adaptive or maladaptive 
under septic and endotoxemic conditions. Of interest, cells overexpressing PGC-1β and mice overexpressing 
PGC-1β selectively in cardiomyocytes were resistant to the LPS-induced decrease of the expression of 
PPARα, ERRα, and enzymes of fatty acid oxidation. PGC-1β transgenic mice showed improvement in 
palmitate oxidation rates in isolated working hearts after treatment with LPS, and echocardiography 
revealed only a modest decrease in cardiac function [68]. These data suggests that impairment in 
mitochondrial energetics may importantly contribute to cardiac dysfunction, and that activation of 
mitochondrial biogenesis may have positive effects in endotoxemia. 
When assessing the role of PPARα in endotoxemia, Drosatos et al. found that LPS administration 
reduced the mRNA expression of PGC-1α/β, PPARα, and metabolic PPARα downstream targets. 
Treatment with a PPARα agonist, however, did not improve cardiac function or alter the mRNA levels 
of these enzymes after endotoxemia. Interestingly, treatment with rosiglitazone, a PPARγ agonist, led 
to an improvement of cardiac dysfunction together with improved expression of PGC-1 molecules and 
Tfam. Moreover, αMHC-PPARγ mice that express PPARγ constitutively in cardiomyocytes showed 
no disturbances in cardiac function and lipid accumulation after LPS treatment [16]. The exact 
mechanism by which PPARγ agonism improves or maintains cardiac function in endotoxemia, and in 
how far these mechanisms are related to mitochondrial biogenesis, remains to be determined. 
3.5. Mitophagy 
Recovery of organ function in sepsis is dependent on removal of dysfunctional mitochondria and 
generation of new, functionally competent mitochondria, as may be achieved by stimulation of 
mitochondrial biogenesis. Removal of dysfunctional mitochondria occurs via autophagy of mitochondria, 
or simply “mitophagy”, which is a quality control mechanism by which cells eliminate dysfunctional 
mitochondria [69]. Damaged mitochondria are selectively sequestered in autophagosomes and 
ultimately degraded following fusion with lysosomes. Different pathways have been described to 
recognize and eliminate the dysfunctional mitochondria. Activation of the PINK1/Parkin (PARK2) 
pathway leads to ubiquitinylation of special substrates of mitochondria that can be recognized by the 
adaptor protein p62, which in turn binds to microtubule-associated protein 1A/1B-light chain 3 (LC3). 
An ubiquitin-independent pathway involves direct binding of autophagy-related protein 8 (ATG8) 
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family proteins to autophagy receptors, such as NIX (Nip3-like protein X) [63,69]. Mitophagy may 
serve to eliminate dysfunctional mitochondria before they induce cellular damage or cell death, but 
may also serve as a cell survival pathway by suppressing apoptosis or as a back-up mechanism when 
the process of apoptosis is defective [70]. 
Several studies have shown that autophagy and mitophagy are increased in various organs in  
sepsis [71,72]. In the heart, several studies observed increased myocardial mRNA or protein levels of 
ATG3, ATG5, ATG7, LC3 II and p62 in LPS-induced endotoxemia, suggestive of increased rates of 
autophagy [14,16,73]. In some cases, a reduced number of cardiomyocyte mitochondria was reported 
in LPS-treated animals [16,25,41] potentially suggesting increased mitochondrial degradation by 
mitophagy, although unchanged mitochondrial mass was observed in other studies [41,74]. An interesting 
study was published by Piquereau et al. who addressed the role of Parkin/PARK2 in mitochondrial 
dysfunction in endotoxemia. LPS treatment led to a 50% decrease in cardiac output and stroke volume 
in wildtype and PARK2−/− mice. While wildtype mice completely recovered cardiac function after 48 h, 
cardiac function remained impaired in PARK2−/− mice. Similarly, a decrease in OXPHOS complex 
activities, mitochondrial O2 consumption rates, and increased susceptibility to mPTP opening  
were normalized 48 h after endotoxemia induction in wildtype but not PARK2−/− mice. Thus,  
PARK2-dependent autophagy/mitophagy is required to recover mitochondrial and cardiac function 
following LPS treatment. In mitochondrial fractions of LPS-treated wildtype mice, levels of 
polyubiquitinated proteins and PARK2 were increased, and proteins involved in mitochondrial quality 
control and autophagy (SQTSTM1, LC3 II, BNIP3L/NIX, and BNIP3) were recruited to mitochondria 
both in wildtype and PARK2−/− mice, showing that septic mitochondria can be targeted for degradation  
by mitophagy, even in the absence of PARK2. Using electron microscopy, the presence of 
autophagosome-like structures was confirmed as well [31]. Thus, mitophagy may be increased in 
endotoxemia and may serve a compensatory role in the recovery of mitochondrial function by 
eliminating defective mitochondria. The occurrence of mitochondrial biogenesis after the early 
activation of mitophagy during the course of endotoxemia suggests that an increase in mitochondrial 
biogenesis may serve to recover an appropriate volume density of mitochondria to restore the full 
mitochondrial energy-producing capacity of the heart [14,75,76]. Recent studies suggest that the 
degradation of mitochondria via mitophagy promotes mitochondrial biogenesis directly via a Toll-like 
receptor 9 (TLR9)-dependent signaling, although the mechanistic links between autophagy and 
mitochondrial biogenesis are not well characterized yet [72]. In contrast to a beneficial role of 
autophagy, the controlled elimination of organelles may also be part of apoptosis. Interactions among 
signaling components of the two pathways (autophagy and apoptosis) have been reported and indicate 
a complex cross-talk [77]. Thus, it remains unclear whether autophagy is actually an attempt to remove 
damaged mitochondria or part of a cellular program leading to apoptosis during sepsis. More studies 
are needed to further define the role of mitophagy in septic cardiomyopathy and to define how 
mitophagy may directly regulate mitochondrial biogenesis. 
4. Conclusions 
Cardiac dysfunction is common in patients suffering from severe sepsis and septic shock. At present, 
treatment mainly includes management of the infectious focus and hemodynamic support. However, 
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recent progress in sepsis research increased our understanding of underlying molecular alterations 
contributing to organ dysfunction, including mitochondrial dysfunction. In the heart, a number of 
mechanisms have been proposed to underlie myocardial mitochondrial dysfunction, including 
excessive production of mitochondrial NO and ROS, increased mPTP opening, and increased 
mitochondrial uncoupling. Several reports showed recovery of mitochondrial function which was 
associated with improvement or normalization of cardiac pump function following treatment with 
drugs that target different mechanisms within mitochondria but that had no influence on the 
inflammatory response, supporting the idea that impaired myocardial energetics rather than cardiac 
inflammation per se are critical for cardiac dysfunction in sepsis [11,23,63]. We now need more 
studies using pharmacological modulators to prevent or reverse specific mitochondrial mechanisms to 
further evaluate the significance of mitochondrial mechanisms in septic cardiomyopathy, and to test 
whether such treatments may be a promising and feasible therapeutic approach that could potentially be 
transferred from bench to bedside. Such approaches may, for example, include inhibition of mitochondrial 
ROS and NO production and inhibition of mPTP opening. In addition, it would be very informative to 
perform such studies in the different models of sepsis and endotoxemia, which may not only reveal 
differences in the underlying disease mechanisms but may also allow evaluating whether the treatment 
may be broadly applicable and effective irrespective of the sepsis model. The increasing interest in 
sepsis research and the availability of novel research tools promises that effective specific treatments 
may be available in the future to complement our current treatment options of severe sepsis and septic 
shock to improve outcome for this highly jeopardized patient cohort. 
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